Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients.

Podcast Summary

Introduction: Dr. Warrick Bishop, a practicing cardiologist and author dedicated to patient education about heart health, hosts this episode featuring Associate Professor David Cahoon, co-president of the Prevention Arm of the Cardiac Society of Australia and New Zealand. The episode discusses a recent debate about the scientific validity of cholesterol management and statin therapy, with Dr. Cahoon representing the evidence-based medical perspective against three prominent figures who challenged conventional cholesterol treatment.

Key Takeaways:

• The "Catalyst" program featuring Marianne de Massey, a non-expert journalist, promoted medically harmful misinformation that led to increased heart attacks, strokes, and mortality when viewers stopped taking statins—demonstrating the dangers of poor science reporting.

• Ross Walker's claim that only 1 in 19 people need statins lacks scientific evidence and contradicts established research showing that for every 1 millimole reduction in LDL cholesterol, there is a 25% reduction in heart attacks and 20% reduction in strokes.

• Claims that cholesterol is needed for hormone production misunderstand basic biochemistry; while cholesterol is used for hormones, the body produces excess cholesterol in every cell, and HDL removes waste LDL particles back to the liver for recycling.

• LDL particles are waste products from the liver's transport of triglycerides and become atherosclerotic only when modified (oxidized, glycosylated) or when inflammation increases endothelial permeability, making lowering LDL levels a valid therapeutic target.

• Dr. Chaffee, a neurosurgical registrar and bodybuilder without lipid metabolism expertise, inappropriately positioned himself as a cholesterol expert and misquoted the Framingham study, claiming it showed low cholesterol increased coronary artery disease.

• Inflammation, while an important factor in atherosclerosis, is not the sole driver of plaque formation; over 60 risk factors exist, with five key ones including smoking, anxiety, and depression that increase LDL atherogenicity.

• Major clinical trials like the Australian Lipid Trial involved independent safety and data monitoring committees that were not corrupt despite pharmaceutical funding; the funding simply covered operational costs, not individual compensation.

• The Australian MIPA trial was the first in the world to demonstrate that lowering LDL by one millimole per litre decreased total mortality by 3% over six years in patients with average cholesterol levels.

• Critics like Dr. Malhotra who lack research involvement themselves question the integrity of researchers while offering no independent data, contradicting evidence-based standards.

• Contemporary statin therapy targets require at least 2 millimole per litre LDL reduction to be considered adequate treatment, and cholesterol discussion should focus on LDL particles rather than general "cholesterol" terminology.